When people think about geological faults, they usually think about earthquakes. Yet faults do not move only during ...

Over the past few decades, engineers have developed various devices that can create holograms, three-dimensional (3D) or ...

There are plenty of radios you can buy that pick up MW and SW bands if that’s what you’re into. Or, you can follow [mircemk]’s example, and whip one up yourself instead. The build employs an ESP32 as ...

AI-powered plugin generators promise to democratise development – but is vibe coding really the future of plugin design, or ...

Google didn't forget AI creators in its latest round of Gemini announcements as part of Google I/O. The company just officially revealed Gemini Omni, a new model that can "create anything from any ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Pills, tablets and capsules on world map with charts blue background. International ...

The Federal Reserve's pause on rate cuts means investors can still grab attractive yields on short-duration assets. The central bank opted to keep the federal funds rate between 3.5% to 3.75% on ...

Feb 27 (Reuters) - Flagship-backed Generate Biomedicines' shares fell more than 6% in their Nasdaq debut on Friday, giving the drug developer a valuation of $1.91 billion, as lingering market ...

Despite wide availability of biologic drugs for asthma, use of these injectable medicines remains low — patients just dislike frequent injections. Generate Biomedicine’s lead drug candidate could ...

Generate:Biomedicines is the latest biotech to benefit from a renewed appetite from investors for publicly listed drug developers. Generate—which will list its stock on the Nasdaq this morning under ...

Feb 26 (Reuters) - Generate Biomedicines said on Thursday that it raised $400 million in its U.S. initial public offering, pricing shares of the U.S.-based drug developer at $16 each. The offering ...

Generate Biomedicines Inc., a biotechnology firm using artificial intelligence in drug development, is seeking to raise as much as $425 millon in an initial public offering, as listing activity in the ...